Please refer the Attachment
Awaiting price reaction for this filing.
The board approved the unaudited standalone and consolidated financial results for Q2 and H1 FY26 (ended September 30, 2025). It also noted the NCLT order dated October 13, 2025 sanctioning the scheme of amalgamation of Medinova with Vijaya Diagnostic Centre Ltd (VDCL), with appointed date April 1, 2024 and record date November 25, 2025. Standalone revenue for Q2 slipped about 4.6% YoY to Rs 188.60 lakh but H1 revenue rose 3.4% to Rs 396.43 lakh. Standalone H1 PAT jumped 43.5% to Rs 59.39 lakh and consolidated H1 PAT rose 27.8% to Rs 117.56 lakh. Other expenses declined, helping operating margins expand notably. The auditor issued an unmodified review report on both sets of results but added an Emphasis of Matter paragraph drawing attention to the pending amalgamation.
The scheme is now NCLT-approved; Medinova shareholders stand to receive 1 VDCL share for every 22 Medinova shares held. The merger should resolve Medinova's negative standalone net worth (Rs -61.34 lakh) since it merges into the larger VDCL. In the near term, the stock may trade on the record date (Nov 25, 2025) and on confirmation of the ROC filing that triggers effective dissolution of the transferor company.